Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,285.50 -21.51 (-0.41%) Dow
39,160.40 -510.64 (-1.29%) Nasdaq
16,810.80 +9.26 (+0.06%) Bitcoin USD
67,802.77 -1,980.20 (-2.84%) CMC Crypto 200
1,474.54 -28.12 (-1.87%)
APLS Jan 2025 70.000 put
| Previous close | 28.41 |
| Open | 28.60 |
| Bid | 29.30 |
| Ask | 30.60 |
| Strike | 70.00 |
| Expiry date | 2025-01-17 |
| Day's range | 28.41 - 28.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 303 |
GlobeNewswireApellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceeds used to buy out existing SFJ Pharmaceuticals development liability Significantly improves liquidity profile by eliminating $366 million in SFJ payments through 2027 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that it has entered into a non-dilutive, senior secured credit facility with Sixth Street, a le
Simply Wall St.Analysts Are Updating Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates After Its First-Quarter Results
There's been a notable change in appetite for Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shares in the week since...
Insider MonkeyApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript May 7, 2024 Apellis Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.54 EPS, expectations were $-0.54. Apellis Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]
